|
|
???tair.name??? >
???browser.page.title.author???
|
"choo s p"???jsp.browse.items-by-author.description???
Showing items 26-30 of 30 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
| 臺大學術典藏 |
2018 |
SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma
|
Ng D.C.E.; Goh B.K.P.; Lo R.H.G.; Tay K.H.; Goh A.S.W.; Low A.S.-C.; Thng C.-H.; Kok K.Y.Y.; Bartlett A.; PO-CHIN LIANG; Chow P.K.H.; Gandhi M.; Tan S.-B.; Khin M.W.; Khasbazar A.; Ong J.; Choo S.P.; Cheow P.C.; Chotipanich C.; Lim K.; Lesmana L.A.; Manuaba T.W.; Yoong B.K.; Raj A.; Law C.S.; Cua I.H.Y.; Lobo R.R.; Teh C.S.C.; Kim Y.H.; Jong Y.W.; Han H.-S.; Bae S.-H.; Yoon H.-K.; Lee R.-C.; Hung C.-F.; Peng C.-Y.; Gebski V.; Mak K.S.W.; Soo K.C.; Liew W.M.; Lekurwale G.; Chow P.K.H.;Gandhi M.;Tan S.-B.;Khin M.W.;Khasbazar A.;Ong J.;Choo S.P.;Cheow P.C.;Chotipanich C.;Lim K.;Lesmana L.A.;Manuaba T.W.;Yoong B.K.;Raj A.;Law C.S.;Cua I.H.Y.;Lobo R.R.;Teh C.S.C.;Kim Y.H.;Jong Y.W.;Han H.-S.;Bae S.-H.;Yoon H.-K.;Lee R.-C.;Hung C.-F.;Peng C.-Y.;Po-Chin Liang;Bartlett A.;Kok K.Y.Y.;Thng C.-H.;Low A.S.-C.;Goh A.S.W.;Tay K.H.;Lo R.H.G.;Goh B.K.P.;Ng D.C.E.;Lekurwale G.;Liew W.M.;Gebski V.;Mak K.S.W.;Soo K.C. |
| 國立成功大學 |
2018 |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle, M.;Lowery, M.;Shroff, R.T.;Weiss, K.H.;Springfeld, C.;Borad, M.J.;Ramanathan, Ramanathan R.K.;Goyal, L.;Sadeghi, Sadeghi S.;Macarulla, T.;El-Khoueiry, A.;Kelley, R.K.;Borbath, I.;Choo, S.P.;Oh, D.-Y.;Philip, Philip P.A.;Chen, L.-T.;Reungwetwattana, T.;Van, Cutsem E.;Yeh, K.-H.;Ciombor, K.;Finn, R.S.;Patel, A.;Sen, Sen S.;Porter, D.;Isaacs, R.;Zhu, A.X.;Abou-Alfa, G.K.;Bekaii-Saab, T. |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 臺大學術典藏 |
2017 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
Showing items 26-30 of 30 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
|
